Your browser doesn't support javascript.
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.
Sturkenboom, Marieke G G; Märtson, Anne-Grete; Svensson, Elin M; Sloan, Derek J; Dooley, Kelly E; van den Elsen, Simone H J; Denti, Paolo; Peloquin, Charles A; Aarnoutse, Rob E; Alffenaar, Jan-Willem C.
  • Sturkenboom MGG; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Märtson AG; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Svensson EM; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Sloan DJ; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Dooley KE; Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
  • van den Elsen SHJ; Liverpool School of Tropical Medicine, Liverpool, UK.
  • Denti P; School of Medicine, University of St Andrews, St Andrews, UK.
  • Peloquin CA; Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Aarnoutse RE; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Alffenaar JC; Department of Clinical Pharmacy, Hospital Group Twente, Almelo, Hengelo, the Netherlands.
Clin Pharmacokinet ; 60(6): 685-710, 2021 06.
Article in English | MEDLINE | ID: covidwho-1275007
ABSTRACT
Tuberculosis (TB) is still the number one cause of death due to an infectious disease. Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB treatment and help to prevent slow response to treatment, acquired drug resistance, and adverse drug effects. The aim of this review was to provide an update on the pharmacokinetics and pharmacodynamics of anti-TB drugs and to show how population pharmacokinetics and Bayesian dose adjustment can be used to optimize treatment. We cover aspects on preclinical, clinical, and population pharmacokinetics of different drugs used for drug-susceptible TB and multidrug-resistant TB. Moreover, we include available data to support therapeutic drug monitoring of these drugs and known pharmacokinetic and pharmacodynamic targets that can be used for optimization of therapy. We have identified a wide range of population pharmacokinetic models for first- and second-line drugs used for TB, which included models built on NONMEM, Pmetrics, ADAPT, MWPharm, Monolix, Phoenix, and NPEM2 software. The first population models were built for isoniazid and rifampicin; however, in recent years, more data have emerged for both new anti-TB drugs, but also for defining targets of older anti-TB drugs. Since the introduction of therapeutic drug monitoring for TB over 3 decades ago, further development of therapeutic drug monitoring in TB next steps will again depend on academic and clinical initiatives. We recommend close collaboration between researchers and the World Health Organization to provide important guideline updates regarding therapeutic drug monitoring and pharmacokinetics/pharmacodynamics.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis / Pharmaceutical Preparations Type of study: Prognostic study Limits: Humans Language: English Journal: Clin Pharmacokinet Year: 2021 Document Type: Article Affiliation country: S40262-021-00997-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis / Pharmaceutical Preparations Type of study: Prognostic study Limits: Humans Language: English Journal: Clin Pharmacokinet Year: 2021 Document Type: Article Affiliation country: S40262-021-00997-0